Vor Biopharma (VOR) Net Cash Flow (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Net Cash Flow data on file, last reported at -$226.6 million in Q1 2026.

• Quarterly Net Cash Flow fell 610.34% year-over-year to -$226.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.6 million (up 2213.22% YoY) and the FY2025 annual result came in at $312.3 million, up 517.31% from the prior year.
• Net Cash Flow slipped to -$226.6 million in Q1 2026 per VOR's latest filing, from $236.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $236.0 million in Q4 2025 and bottomed at -$226.6 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$10.2 million (2023), against an average of $2.8 million.
• The widest annual swing landed in 2025, when Net Cash Flow jumped 709.66%; it then plunged 610.34% in 2026.
• Tracing VOR's Net Cash Flow over 5 years: stood at -$3.1 million in 2022, then slumped by 337.87% to -$13.7 million in 2023, then surged by 313.31% to $29.2 million in 2024, then jumped by 709.66% to $236.0 million in 2025, then plunged by 196.01% to -$226.6 million in 2026.
• Per Business Quant, the three latest VOR Net Cash Flow figures stand at -$226.6 million (Q1 2026), $236.0 million (Q4 2025), and -$32.4 million (Q3 2025).

Peer Comparison